Mirtazapina Mylan Generics Italia (Mirtazapine)

Mirtazapine blocks presynaptic α2‑adrenergic receptors, leading to increased release of norepinephrine and serotonin. It also antagonizes 5‑HT2, 5‑HT3 and H1 receptors, which together produce antidepressant effects and a characteristic sedative profile that can improve sleep.

The appropriate dose of mirtazapine is determined by the prescribing clinician based on the individual’s clinical condition, response, and tolerability. Dosage may start low and be adjusted gradually; patients should follow the specific instructions provided by their healthcare professional.

The safety of mirtazapine during pregnancy or lactation has not been definitively established. Healthcare providers usually weigh potential benefits against possible risks and may consider alternative treatments. Women who are pregnant, planning pregnancy, or breastfeeding should discuss options with their physician.

To request supply, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirtazapine belongs to the NaSSA class, differing from SSRIs and SNRIs by its dual antagonism of α2‑adrenergic and certain serotonin receptors, and its strong H1 blockade. This profile often results in pronounced sedation and weight gain, which can be advantageous for patients with insomnia but may be less desirable for those concerned about metabolic effects.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original container, protect from moisture and direct sunlight, and ensure they are out of reach of children. Do not store in the refrigerator or freezer.

Mirtazapina Mylan Generics Italia is taken orally, usually once daily in the evening due to its sedative effect. Tablets should be swallowed whole with water and not crushed or chewed unless otherwise directed by a healthcare professional.

Serious adverse events include severe blood disorders such as agranulocytosis, hepatic dysfunction, seizures, and the emergence or worsening of suicidal thoughts, particularly early in treatment. Patients should seek immediate medical attention if they experience signs of infection, jaundice, unexplained seizures, or intense mood changes.

Mirtazapine is contraindicated in patients who have taken monoamine oxidase inhibitors (MAOIs) within the past 14 days. Caution is also advised for individuals with known hypersensitivity to mirtazapine, severe hepatic impairment, or those at high risk for suicidal behavior. A prescriber should evaluate each case individually.